Match!
Chanhee Han
Yale University
18Publications
4H-index
26Citations
Publications 18
Newest
Ovarian cancer is the most common cause of gynecologic cancer death in the United States with 22,530 newly diagnosed cases and 13,980 deaths annually. There has been a miniscule, approximately 2.3% decrease, each year in the death rates from ovarian cancer over the past few decades (1). Although most patients with advanced ovarian cancer respond to initial platinum-based chemotherapy, 70% will relapse and ultimately become resistant, refractory, or unable to receive platinum-based chemotherapy o...
#1Luca Zammataro (Yale University)H-Index: 16
#2Salvatore Lopez (Yale University)H-Index: 14
Last.Alessandro D. Santin (Yale University)H-Index: 31
view all 45 authors...
The prognosis of advanced/recurrent cervical cancer patients remains poor. We analyzed 54 fresh-frozen and 15 primary cervical cancer cell lines, along with matched-normal DNA, by whole-exome sequencing (WES), most of which harboring Human-Papillomavirus-type-16/18. We found recurrent somatic missense mutations in 22 genes (including PIK3CA, ERBB2, and GNAS) and a widespread APOBEC cytidine deaminase mutagenesis pattern (TCW motif) in both adenocarcinoma (ACC) and squamous cell carcinomas (SCCs)...
#1Anna Bianchi (Yale University)H-Index: 4
#2Salvatore Lopez (Yale University)H-Index: 14
Last.Alessandro D. Santin (Yale University)H-Index: 31
view all 22 authors...
Abstract Objectives Cervical cancer (CC) remains a major health problem worldwide. Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors (PARPi) have emerged as a promising class of chemotherapeutics in ovarian cancer. We explored the preclinical in vitro and in vivo activity of olaparib against multiple primary whole exome sequenced (WES) CC cells lines and xenografts. Methods Olaparib cell-cycle, apoptosis, homologous-recombination-deficiency (HRD), PARP trapping and cytotoxic...
12